Print

Conference on Retroviruses and Opportunistic Infections (CROI 2017)

Expanding access to simpler, more optimal HIV treatment regimens for children and adults has been a top priority for UNITAID since its creation over ten years ago.  UNITAID and WHO are working closely with key partners across the global health landscape to advance the optimisation of antiretroviral treatment (ARV) for low- and middle-income countries.

UNITAID’s Executive Board recently approved over US$ 68 million to support ART optimisation efforts, bringing its HIV treatment portfolio to a total of US$ 110 million. The newly-approved grants aim to demonstrate the efficacy and robustness of new optimal regimens in low- and middle-income countries, and lay the groundwork for scale-up by unlocking the market.

The new grants include four clinical trials individually implemented by:

  • The French National Agency for Research on AIDS and Viral Hepatitis (ANRS) and Institut Bouisson Bertrand (France) – trial name NAMSAL/ANRS 12313
  • University of Liverpool (UK) – trial name DolPHIN2
  • University of New South Wales (Australia) – trial name D2EFT
  • Wits Reproductive Health and HIV Institute (South Africa) – trial name ADVANCE (co-funded with USAID)

The new grants will be launched at an event on 12 February ahead of the annual Conference on Retroviruses and Opportunistic Infections (CROI 2017), being held in Seattle, Washington from 13-16 February (www.croiconference.org).